Astellas sells US production site to APP
This article was originally published in Scrip
Executive Summary
Astellashas sold a US manufacturing facility in Grand Island, New York, toAPP Pharmaceuticals. The move forms part of a wider reduction in production facilities under Astellas's current mid-term business plan, which calls for cutting the number of these to around 10 worldwide by April 2011. The Japanese firm will continue to lease the facility from APP until next spring, when it will transfer the production of the atopic dermatitis product Protopic (topical tacrolimus) from there to its Toyama plant in Japan. APP, a US firm specialising in generic injectables, already has operations on Grand Island and will offer employment to most of the 90 or so employees at the former Astellas facility.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Bayer won’t split, for now; Pfizer’s next-gen ADC pipeline; oncology dominates investment but other areas grow; goodbye NASH, hello MASH; and BMS’s CEO gives his views on India.